Agios Pharmaceuticals, Inc.

NASDAQ:AGIO

Biotechnology

Healthcare
$28.76 +1.50%

+$0.50 today

Market cap
$1.72B
Beta
0.59
P/E (TTM)
-4.7
EPS (TTM)
-$7.19
52W Low $22.24High $46.00

Volume 0.47M

Average 1.11M

Income Statement

Follow revenue through to earnings.

Revenue

$54.03M

FY 2025 · Annual

+48.0% YoY

Operating Income

-$472.13M

FY 2025 · Annual

Net Income

-$412.78M

FY 2025 · Annual

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue014.24M26.82M36.5M54.03M
Cost of Revenue18.78M1.7M9.5M4.17M11.52M
Gross Profit(18.78M)12.54M17.32M32.33M42.51M
Gross Margin—88.0%64.6%88.6%78.7%
Research & Development256.97M279.91M288.9M301.29M334.36M
Selling, General & Admin121.45M121.67M119.9M156.78M180.28M
Operating Expenses359.64M401.58M408.81M458.07M514.64M
Depreciation & Amortization18.78M8.56M6.62M5.65M5.18M
EBITDA(337.73M)(223.24M)(345.47M)723.62M(408.62M)
EBITDA Margin—-1567.7%-1287.9%1982.6%-756.3%
Operating Income(378.42M)(389.05M)(391.49M)(425.74M)(472.13M)
Operating Margin—-2732.1%-1459.5%-1166.5%-873.9%
Interest Income836K12.79M33.34M48.08M56.38M
Interest Expense00000
Other Income / Expenses21.91M157.25M39.4M1.14B58.34M
Income Before Tax(356.51M)(231.8M)(352.09M)717.97M(413.8M)
Pre-Tax Margin—-1627.8%-1312.6%1967.1%-765.9%
Income Tax Expense00044.24M(1.02M)
Net Income1.6B(231.8M)(352.09M)673.73M(412.78M)
Net Margin—-1627.8%-1312.6%1845.9%-764.0%
EPS (Basic)(6.36)(4.23)(6.33)11.86(7.12)
EPS (Diluted)(6.36)(4.23)(6.33)11.64(7.12)
Weighted Avg Shares60.45M54.79M55.65M56.81M57.97M
Weighted Avg Shares (Diluted)60.45M54.79M55.65M57.89M57.97M

AGIO Earnings Waterfall · TTM

NASDAQ:AGIO · Revenue to Net Income

Key Ratios

EPS$-7.25
Gross Margin81.0%
Net Margin-680.3%
P/E Ratio-4.7
P/S Ratio127.8

Analysis

$66.0M of revenue converted into -$422.6M of net income for the selected period. Gross margin is 81.0% and net margin is -680.3%, showing how much revenue survives after costs and taxes. EPS is $-7.25, tying the income statement back to per-share earnings.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
SC 13GSC 13G filingNov 13, 2026
8-KCurrent reportNov 5, 2026
10-QQuarterly reportNov 5, 2026
4Statement of changes in beneficial ownershipOct 28, 2026
4Statement of changes in beneficial ownershipOct 23, 2026

How much revenue does AGIO generate?

Agios Pharmaceuticals, Inc. (AGIO) reported $54.03M of revenue in fiscal 2025.

Is AGIO profitable?

Agios Pharmaceuticals, Inc. (AGIO) reported -$412.78M of net income, with a net margin of -764.0%.